Evidence map›Paper›PMID 41251338›Full record

ArticleTurkish journal of pharmaceutical sciences2025

Pharmacoeconomics Education in Pharmacy Faculties: Status in Türkiye and Other Countries.

Harun Kızılay

Abstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Harun KızılaySelçuk University Faculty of Pharmacy, Department of Pharmacology, Konya, Türkiye.ORCID 0000-0003-3660-0721

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Pharmacoeconomics is an important branch of science that should be taken into account by countries' social security institutions in order to rationally manage drug expenditures within healthcare budgets for the aging population. Pharmacists trained in pharmacoeconomics make a great contribution to this field. This study aims to draw attention to the inclusion of pharmacoeconomics education as a compulsory course in the curricula of pharmacy faculties in Türkiye. Materials and Methods: Fifty-one pharmacy faculties in Türkiye were analysed. The pharmacoeconomics courses and their contents in the curriculum of these faculties were evaluated. The course contents, European Credit Transfer System and credits, weekly and meeting hours of the faculties offering pharmacoeconomics courses were analyzed. Results: There are 51 pharmacy faculties in Türkiye. Of these pharmacy faculties, 33 are operating under state universities and 18 under foundation universities. There is no pharmacoeconomics course in the curriculum of 82.35% of the pharmacy faculties (n=42). In the other 17.65% (n=9) of the faculties, there is a pharmacoeconomics course in the curriculum. The course contents of the faculties are similar, and basic pharmacoeconomics information is generally given. There are no faculty members who have completed their PhDs in this field. Conclusion: This study, the first to systematically evaluate the situation in all pharmacy faculties in Türkiye, has revealed that pharmacoeconomics education is limited. Making pharmacoeconomics courses mandatory in the curriculum of pharmacy faculties is necessary to comply with international standards and enable pharmacists to contribute more effectively to rational drug use and the sustainability of healthcare systems.

Indexed as

health expendituresPharmacoeconomicspharmacy curriculumpharmacy educationTürkiye

Identifiers

PMID41251338
PMCPMC12628028

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.